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ABSTRACT
Summary: Cancer is an evolutionary disease, and there is increasing interest 
in applying tools from evolutionary biology to understand cancer progression. 
Restriction-site associated DNA sequencing (RADseq) was developed for the field 
of evolutionary genetics to study adaptation and identify evolutionary relationships 
among populations. Here we apply RADseq to study tumor evolution, which allows for 
unbiased sampling of any desired frequency of the genome, overcoming the selection 
bias and cost limitations inherent to exome or whole-genome sequencing. We apply 
RADseq to both human pancreatic cancer and zebrafish melanoma samples. Using 
either a low-frequency (SbfI, 0.4% of the genome) or high-frequency (NsiI, 6-9% of 
the genome) cutter, we successfully identify single nucleotide substitutions and copy 
number alterations in tumors, which can be augmented by performing RADseq on 
sublineages within the tumor. We are able to infer phylogenetic relationships between 
primary tumors and metastases. These same methods can be used to identify somatic 
mosaicism in seemingly normal, non-cancerous tissues. Evolutionary studies of cancer 
that focus on rates of tumor evolution and evolutionary relationships among tumor 
lineages will benefit from the flexibility and efficiency of restriction-site associated 
DNA sequencing.
INTRODUCTION
The characterization of cancer as an evolutionary 
process was reviewed by Peter Nowell four decades 
ago. He hypothesized a stepwise progression of acquired 
variation and natural selection to explain the emergence 
and increasing aggressiveness of tumors [1]. Since then, 
data from cancer genomics, multi-region sequencing, 
and single-cell sequencing have provided new insight 
into the complex clonal evolution of tumors and the 
extensive genetic heterogeneity present within and 
between cancer patients. The mechanisms underlying 
the generation and maintenance of tumor diversity are 
of particular interest to those seeking to understand 
disease progression and therapeutic resistance of 
advanced cancers. A multidisciplinary approach has been 
increasingly applied to problems of clonal evolution 
in cancer [2-6]. Theory and tools from evolutionary 
biology have been applied to the field of cancer biology 
to understand the rates of accumulation of mutations in 
cellular lineages [5, 7], spatial and temporal patterns of 
intratumor heterogeneity [8-10], the timing and order of 
metastatic progression [11-14], and optimal strategies 
for therapeutic dosing and schedules [15-17]. However, 
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a large disciplinary divide still exists between cancer 
biology and evolutionary biology, and potentially useful 
theoretical and experimental tools have yet to be applied 
across disciplines.
Restriction-site associated DNA sequencing 
(RADSeq) was initially developed for studies of 
evolutionary genetics and has proven to be a powerful 
tool in this field. This method has been largely overlooked 
in cancer biology, which instead relies almost exclusively 
on whole-genome sequencing and exome sequencing to 
discover and quantify genetic variation in tumors (see 
Figure 1 for a comparison of the three methods). Like 
exome sequencing, RADSeq is a reduced-representation 
sequencing approach that targets a subset of the genome. 
However, instead of targeting exonic regions for 
sequencing, the RADseq protocol targets regions of the 
genome flanking restriction enzyme cut sites. Several 
variations of RADseq have been described [18-24]. In 
brief, high quality genomic DNA is first digested with a 
restriction enzyme. Then, sequencing adapters (double-
stranded oligos compatible with a next generation 
sequencing platform) are ligated onto the characteristic 
sticky ends generated by the restriction enzyme digestion. 
The highly-specific ligation of sequencing adapters to 
digested cut sites allows for the targeted sequencing of 
regions flanking these positions, therefore no capture step 
is required. Barcode sequences can also be included in 
the adapter oligos to allow for multiplexed sequencing of 
multiple samples in the same sequencing lane. 
RADseq is a highly flexible approach because the 
proportion of the genome targeted for sequencing can 
be controlled through the choice of restriction enzyme. 
Common cutters (typically enzymes with a shorter 
recognition sequence,) will target a higher percentage of 
genome for sequencing than rare cutters. This means that 
common cutters can be used for questions that require 
more sequence information per genome, for example 
to distinguish between recently-diverged populations 
(e.g. primary tumors vs. metastases) or tumors with low 
mutation rates/burdens (e.g. pediatric tumors). Rare cutters 
can be selected for research questions that call for fewer 
sites per genome and a greater depth of sequencing per 
site (e.g. heterogeneity questions), or benefit from a large 
number of samples (e.g. many tumor sites or patients). 
RADseq differs from whole-exome sequencing in 
that it does not specifically target functional regions of 
the genome. Restriction cut sites occur throughout the 
genome, largely without bias, and thus the sequenced 
regions will represent coding DNA as well as many 
intergenic and other non-coding sites where non-coding 
RNAs might be transcribed as well. This important 
distinction means that RADseq will likely not be the most 
efficient method to identify driver mutations and protein 
changes responsible for the cancer phenotype. However, 
RADseq does have the potential to be a more useful tool 
than exome sequencing to study tumor phylogenetics 
and intrinsic mutation rates, for which neutrally evolving 
sites provide the most robust information [25-27]. These 
differing strengths make whole-exome sequencing and 
RADseq complimentary methods for a variety of cancer 
biology questions. Here we test the utility of RADseq 
for cancer genomics by applying RADseq to a zebrafish 
model of melanoma and to human pancreatic tumors.
RESULTS
Transgenic zebrafish model of melanoma
Performance
We applied RADseq to a zebrafish model of 
melanoma to identify mutations from matched pairs 
of tumor and normal tissue (Figure 2A). Transgenic 
p53-deficient zebrafish expressing the mutant form of 
human BRAF(V600E) in melanocytes spontaneously 
develop melanoma at 4-12 months of age ; 
Tg(mitfa:BRAF(V600E)); p53-/- [28, 29]. We dissected 
melanoma tumors and normal skin from three adult fish 
and used the restriction enzyme SbfI (a rare cutter, with 
an 8bp recognition sequence) to prepare RADseq libraries 
for sequencing on the Illumina platform (HiSeq2500). 
In silico analysis using the zebrafish reference genome 
[30] predicts 30,667 SbfI restriction enzyme cut sites 
in the genome. Because the recognition sequence of the 
restriction enzyme is palindromic, each occurrence of 
the recognition sequence results in two cuts, one on each 
opposing DNA strand. This generates sequence coverage 
in both directions from the cut site [22, 23]. We sequenced 
100bp flanking both sides of each cut site in the 1.4Gb 
genome, resulting in representation of approximately 0.4% 
of the genome. The average depth of coverage for these 
loci was ~350x, and coverage was even across loci (358x 
mean, 337x median).
After filtering reads for quality, we found that 91.5% 
of sequencing reads successfully mapped to the zebrafish 
reference genome and 94.2% of these reads mapped 
specifically to the predicted cut site regions. This degree 
of specificity is striking, especially considering the high 
genetic divergence between different experimental lines 
of zebrafish, including differences between our lab strains 
and the sequenced reference line that we used to predict 
cut sites [31, 32]. 
Mutation-calling in tumors
RADseq data can be analyzed using standard tools 
for alignment to a reference genome and genotyping/
mutation calling [19]. We aligned reads to the zebrafish 
(danRer7) reference genome using BWA [33] and 
identified mutations with MuTec [34] (see methods). By 
comparing melanoma tumor to normal skin for each adult 
fish, we were able to identify single nucleotide variants 
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(SNVs). The total number of SNVs identified in the three 
adult fish tumors were 3, 8, and 5 (Figure 2B). These 
numbers are consistent with previous characterization 
of engineered zebrafish melanomas from whole exome 
sequencing which capture ~3% of the genome and find 
low mutational burden on average, with significant 
variation among tumors [35]. 
Restriction enzyme selection
To demonstrate how the choice of restriction 
enzyme influences the number of mutations captured 
with RADseq, we used the same genomic DNA from 
one of the SbfI-digested fish described above and made 
an additional RADseq library using a more frequently-
cutting enzyme, NsiI (a 6bp recognition sequence). In 
silico analysis predicts 687,595 NsiI cut sites in the 
Figure 1: A. Comparison of whole-genome, exome and RADseq approaches to cancer genome. Whereas whole genome sequencing 
allows for an unbiased view of the genome, it requires high cost when high sequencing depth is needed. Exome sequencing is a reduced 
representation approach that is cost-effective but gives a highly biased view of only protein coding genes, which are under selection in many 
cancers. RADseq uses restriction sites naturally dispersed across the genome at both intergenic as well as coding regions, combining the 
benefits of whole-genome and exome sequencing to allow for unbiased, high sequencing depth in a highly cost effective manner. B. Specific 
features of the 3 methods as they apply to cancer biology.
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Figure 2: Applying RADseq to a zebrafish model of melanoma. A. A transgenic zebrafish model in which the mitfa promoter 
drives human oncogenic BRAFV600E. The embryos (left) and young adults (center) are relatively normal, but all adults (right) develop 
clinically overt melanomas within 4-12 months. Genomic DNA was isolated from a melanoma as well as surrounding skin in four of these 
transgenic animals and RADseq libraries were created from gDNA using either SbfI (0.4% of the genome) or NsiI (9% of the genome). 
B. The efficiency of reads mapping to restriction enzyme cut sites in the genome, along with the depth of coverage and the number of 
mutations discovered in each melanoma. We found a small number of mutations in 3 melanomas when sampling 0.4% of the genome. 
For one fish, the same genomic DNA was used for RADseq with NsiI, and shows a much higher number of mutations, given the greater 
coverage of the genome. C. A fate-mapping transgenic line was created to assess the efficiency of RADseq on subpopulations of cells. The 
mitf-BRAF;p53 model was bred with a fluorescent color “switch” line in which a floxed GFP cassette can be swapped for an mCherry 
cassette upon Cre-mediated recombination. This cross was injected with a melanocyte-specific mitf-CreERT2 plasmid. Upon endoxifen or 
tamoxifen treatment, a subset of the melanocytes in the skin as well as within the melanoma switched from GFP to mCherry. Genomic DNA 
was extracted from either the bulk tumor/skin, or from FACS sorted mCherry+ melanocytes from the tumor/skin pair. D. Overall variant 
allele fractions across all mutations in the sorted vs. unsorted populations showed a significant increase in the mCherry+ subpopulations 
(*,p < 0.05, t-test). E. Individual mutation variant allele fractions are shown, consistently demonstrating increased sensitivity in the sorted 
population, which facilitates higher-confidence mutation calling in subclonal populations.
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zebrafish genome, and again we found our reads mapped 
to these regions with an on-target rate greater than 90%. 
Sequencing 100bp flanking each side of these cut sites 
results in representation of approximately 9% of the 
zebrafish genome. As expected, with many more bases 
in the genome represented in the NsiI library, the number 
of mutations was greater than for the SbfI library - we 
detected 47 mutations in NsiI-flanking regions versus the 
5 mutations detected in the SbfI-flanking regions of the 
same melanoma tumor (Figure 2B and Supplemental Table 
1). 
Lineage-tracing model to study tumor evolution of 
subclonal populations
One of the challenges to studying genetic evolution 
in tumors is heterogeneity - multiple subclonal tumor 
lineages typically make up a single biopsy or tissue 
sample [36]. In addition, normal cells such as fibroblasts 
and immune cells are present within a dissected tumor 
sample, at varying frequencies [37]. This means that 
typical libraries prepared for tumor sequencing represent 
a mixture of cells with different genotypes. Single-cell 
sequencing has promise to overcome some of these 
challenges, but it remains technically difficult and 
expensive to characterize comprehensive mutational 
profiles from single cells [38]. 
We developed a transgenic zebrafish with 
an inducible system to selectively trace subsets of 
melanocytes both in normal skin as well as within the 
melanoma (Figure 2C). We started with an existing 
zebrafish line (ubi:Switch) [39, 40] that possesses 
a ubi:loxP- GFP-loxP-mCherry cassette. These 
Figure 3: RADseq can identify somatic mosaicism. A. Multiple normal tissues were extracted from both WT and BRAF;p53 
fish, including brain, skin, blood, liver, and spleen. Genomic DNA was isolated and RADseq performed using NsiI. As shown in A., these 
tissues represent ontologically distinct origins from the zygote. B. Mutations were detected in the melanoma as expected.  In addition, a 
somatic mutation was identified and validated in the seemingly-normal brain of the BRAf;p53 fish, an area devoid of BRAF expression. 
C. No somatic mutations were detected in any of the tissues derived from the WT animal. D., E. The RADseq library was used to detect 
copy number changes in the above tissues. This revealed two significant copy number amplifications on chromosome 6 in the melanoma, 
whereas all other tissues from both WT and BRAF;p53 were largely diploid.
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Figure 4: RADseq is adaptable to human cancer specimens. A. Through a rapid autopsy program, tissues were obtained from a 
patient with metastatic pancreatic ductal adenocarcinoma (PDAC). These included three tumor-free normal tissues (lung, spleen, kidney), 
the primary pancreatic tumor, and a mesenteric metastasis. Genomic DNA was isolated from these tissues and subject to RADseq using 
NsiI. B. We identified 168 mutations in the metastasis and 164 mutations in the primary tumor. C. An example IGV plot showing the same 
mutation on chromosome 20 identified by RADseq (top) and whole-genome sequencing (bottom). RADseq shows bidirectional reads 
emanating from the cut site, in contrast to the random tiling of reads in the whole-genome approach. D. Mutations in the primary tumor and 
metastasis were used to construct a phylogenic tree depicting the evolutionary history among the sequenced populations. 160 mutations are 
present in the primary tumor and metastasis, indicating that these mutations were already present in the ancestral population that gave rise 
to the two tumors. Four mutations are unique to the primary tumor, and eight mutations are unique to the metastasis, indicating that these 
mutations occurred after the two populations diverged.
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fish ubiquitously express GFP until exposed to Cre 
recombinase, which induces a deletion of the GFP coding 
region and expression of mCherry. We crossed these 
zebrafish with the (p53-/-; mitfa-BRAFV600E +/+) zebrafish 
line that spontaneously develops melanoma. Into this 
background, we injected an inducible Cre transgene 
(mitfa:CreERt2-SV40) under the control of the mitfa 
melanocyte-specific promoter [41]. Exposure to the drug 
Tamoxifen induces Cre-mediated excision of the GFP-
lox complex in melanocytes specifically, causing those 
cells to express mCherry, while the rest of the somatic 
cells continue to express GFP. We screened for fish that 
successfully integrated the transgene into their germline 
and whose offspring show a strong and specific switching 
of GFP to mCherry expression in melanocytes. The 
result is a stable line of melanoma-prone zebrafish with 
inducible fluorophore-based lineage tracing in melanocyte 
lineages. These fish can be treated with tamoxifen as 
embryos or adults to induce an irreversible color change in 
melanocytes. After the drug is removed, the labeled cells 
continue to express mCherry, and they pass this change on 
to their daughter cells, resulting in labeled clonal lineages 
that can be separated from other cells using FACS.
We found that the RADseq method can be used to 
identify mutations in sorted tumor populations from these 
animals. We applied tamoxifen to fish with melanoma 
tumors to label melanocytes in tumors and normal skin 
before dissection. We dissected tissue, disassociated cells, 
and used FACS to separate the mCherry+ melanocytes 
from contaminating stromal cells, and prepared the cells 
for downstream sequence analysis. We also reserved a 
portion of each dissected tissue for traditional RADseq 
analysis of the unsorted population. Nine mutations 
were identified in both the sorted and unsorted analyses. 
These mutations show a significantly higher frequency 
in the sorted (M = 30.56) than the unsorted (M = 25.67) 
population; t(8) = 7.72, p < .0001 (Figure 2D/E and 
Supplemental Table 2) which is consistent with the 
expectation that the specific sorting of melanocytes 
allowed us to reduce the number of contaminating 
normal cells in the sample. We believe this system will 
provide a powerful system to isolate and study subclonal 
populations of normal and tumor melanocytes throughout 
development. 
Capturing somatic mosaicism with RADseq
We dissected and sequenced different tissues from 
a melanoma-prone zebrafish and a wild-type zebrafish 
to test whether acquired genetic variation could be also 
be detected in somatic lineages other than the tumor 
population, given that the fish were p53 deficient in all 
tissues. To do so, we dissected two additional normal 
tissues, brain and liver, to supplement the skin and 
melanoma samples from one of the transgenic fish 
described above. We also isolated brain, skin, blood and 
liver samples from a wild-type zebrafish. Our selection 
of skin, blood, and liver was based on the fact that these 
tissues are derived from different developmental germ 
layers (ectoderm, mesoderm, and endoderm, respectively) 
and therefore form distinct lineages early in embryonic 
development and have the most potential to acquire 
distinct somatic changes (Figure 3A). The brain is derived 
from the ectoderm along with skin, and we included this 
additional tissue because acquired somatic mosaicism 
has been previously described in this organ [42-45]. We 
used SbfI to RAD-sequence each of these tissues (see 
Supplemental Table 3 for RADseq metrics), and detected 
a somatic mutation specific to the brain sample of the 
transgenic fish (i.e. a polymorphism present in the brain 
tissue, but not in the liver, skin, or melanoma tumor from 
that same animal) (Figure 3B). We confirmed the presence 
of this mutation in the brain (and absence in other tissues) 
through targeted PCR of the original genomic DNA and 
additional deep sequencing of the PCR amplicons to 
~1000x coverage in a subsequent HiSeq run. The mutation 
has a frequency of over 20% in the brain, which indicates 
that the mutation likely occurred early in development. We 
did not detect derived mutations in any tissues of the wild-
type fish (Figure 3C). 
Assessing copy number alterations with RADseq
RADseq has been previously shown to be an 
effective tool to identify copy number alterations in 
human tumors [46]. To our knowledge, this study by 
Zheng et al. is the only previous application of the 
RADseq method to cancer. We analyzed the SbfI-digested 
RADseq samples from normal and melanoma tissue 
from melanoma-prone and wild-type fish for evidence 
of copy number alterations. We identified two regions 
of chromosome six in the melanoma tumor sample that 
show strong evidence of amplification (Figure 3D). These 
regions contain 116 genes, and are not among previously-
documented recurrently amplified regions in engineered 
zebrafish melanomas [35]. Although we cannot evaluate 
the functional importance of copy number alterations 
from sequence data alone, the amplified regions do 
contain several genes of interest including the zebrafish 
ortholog of the human transcription factor, Myc, which 
is a frequently mutated oncogene in humans including 
amplification/overexpression in 6% of melanomas in the 
TCGA database [47, 48]. 
We did not detect any copy number changes in 
any of the normal tissues of the melanoma-prone fish 
or the wild-type fish (Figure 3E). RADseq has specific 
advantages for studies of copy number alterations because 
the selection of restriction enzyme sets the resolution at 
which copy number change events can be detected. A 
frequently-cutting enzyme will produce a high density of 
markers throughout the genome to identify amplifications 
and deletions of small genomic regions. A rare cutter 
will produce a lower density of markers spread across 
the genome, and can be used to identify amplifications 
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and deletions of large genomic regions, with very low 
sequencing cost.
Human pancreatic cancer samples from primary 
and metastatic sites
A unique feature of RADseq is that the same 
protocol and reagents can be used for any species because 
there are no sequence-specific capture steps (e.g. exonic 
baits) involved. We used the enzyme NsiI to generate 
RADseq libraries for tissue samples obtained from a 
human pancreatic cancer patient through a rapid autopsy 
program (Figure 4A) [11]. In silico analysis using the 
human reference genome hg19 predicts 922,636 NsiI 
cut sites in the genome. Sequencing 100bp flanking 
both directions of each cut site results in representation 
of approximately 6% of the human genome. Note that 
this is a larger fraction of genome coverage than is 
targeted by common exome capture kits which typically 
represent approximately 50-65Mb (~2% of the human 
genome). Similar to performance in zebrafish described 
above, RADseq showed very high efficiency with the 
NsiI enzyme in human tissues (see Supplemental Table 
4 for RADseq metrics). After filtering for quality, 92.4% 
of reads successfully mapped to the human reference 
genome. 97.0% of these reads mapped to the predicted 
cut site regions, and 99.28% of predicted cut site regions 
received sequence coverage. The average depth of 
coverage was ~50x (52x mean, 49.6x median). 
The tissues included in this study were primary 
pancreatic tumor, mesentery metastasis, and normal 
spleen. These tissues had already undergone whole-
genome sequencing (WGS), and thus provided an 
independent and comprehensive sequence dataset that we 
could use to validate RADseq performance for identifying 
mutations. After filtering for quality, we aligned reads 
to the reference genome using BWA, and we called 
mutations with MuTect. We identified 168 mutations 
distinguishing the metastasis from the normal sample 
and 164 mutations distinguishing the primary tumor 
from the normal sample (Figure 4B and Supplemental 
Table 5 for a list of all mutations detected). 116 (67%) 
of the 172 total unique mutations that we detected fall in 
intergenic regions, 53 (31%) are in introns, and 3(2%) 
are in exons (an example of which is shown in Figure 
4C). This distribution is consistent with the composition 
of the human genome, and supports the prediction that 
RADseq loci are distributed approximately randomly in 
the genome and that the majority of mutations detected 
will be functionally neutral. Of the three exonic mutations, 
one was silent and two were missense mutations, in codon 
12 of KRAS and exon 49 of FBN1. The mutation that we 
detected in codon 12 of KRAS (G12D) is a common and 
important driver in pancreatic and other cancers and is 
concordant with that found by whole genome sequencing 
of these same samples [49-51]. Although RADseq is not 
an efficient method to search for driver genes in cancer, 
there happens by chance to be an NsiI cut site adjacent to 
this important region, thus cut sites adjacent to hot spots 
can also identify somatic variants of importance. 
To compare results between RADseq and WGS, we 
independently analyzed sequence data from the whole-
genome sequence library. All reads were aligned against 
the human reference genome, and we used MuTect to 
identify single nucleotide variants. For efficiency, we 
restricted mutation calling to regions of the genome 
adjacent to NsiI cut sites. The whole-genome sequence 
libraries confirmed the presence of 100% of the RADseq-
detected variants. 
We used mutation information from primary tumor 
and metastasis to infer a phylogenetic tree that depicts 
the evolutionary history underlying tumor progression 
(Figure 4D). 160 mutations occur before the primary 
tumor and metastasis lineages diverge. 8 mutations occur 
along the metastasis lineage, and 4 mutations occur in the 
primary tumor lineage after its split from the metastasis 
lineage. These results are consistent with previous studies 
of pancreatic cancer patients that show a long history of 
shared mutations among primary tumors and metastases, 
with fewer unique mutations distinguishing individual 
tumors within patients [11]. 
DISCUSSION
When applied to the appropriate research questions, 
RADSeq provides an efficient, flexible and cost effective 
method to utilize the power of next-generation sequencing 
technologies to gain new insights into the ecological and 
evolutionary dynamics of cancer. Some additional details 
regarding study design and analysis will be useful for 
cancer biologists employing this technique.
Study design: When designing a RADseq 
experiment, the choice of restriction enzyme will 
determine the number of loci represented in each sequence 
library. It is important to have an expectation for the 
number of cut sites produced by potential restriction 
enzymes in order to design an experiment that will provide 
sufficient genetic resolution for the research question, and 
to anticipate how much sequencing will be required to 
achieve a given depth of coverage per site. The simplest 
estimate is that an 8-cutter will cut every 48 = 65,536bp 
and a 6-cutter will cut every 46 = 4,096bp, but many 
genomes and enzymes will deviate significantly from 
this expectation [19]. The calculation can be improved by 
accounting for the GC content of the cut site and genome 
under study, however, the most accurate estimates for 
numbers of cut sites can be obtained through in silico 
analysis from a published reference genome for the 
species under study. Computational tools exist to help 
plan an appropriate sequencing effort for a given target 
depth by estimating the number of loci expected for a 
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given protocol and genome [52]. The number of bases 
represented per genome will also be determined by the 
read length of the sequencing technology (typically up to 
150bp reads currently with Illumina, for example). Most 
questions can be sufficiently addressed with short reads 
and single-end sequencing, but longer reads can also be 
obtained by assembling contigs from paired-end sequence 
reads.
Quality and quantity of starting material: RADseq 
library preparation protocols have been optimized for 
high-molecular weight genomic DNA, and are not 
expected to perform as well with highly degraded DNA 
such as that obtained from FFPE tissue [53]. In degraded 
samples, small fragments of starting DNA not adjacent to 
cut sites may end up in the sequencing library and waste 
sequencing effort on off-target loci. Also, the mechanical 
shearing step to produce fragments of optimal size for 
the sequencing platform works best with relatively large 
fragments present after enzyme digestion. In addition 
to high quality DNA, a large quantity of starting DNA 
is beneficial because it can reduce the number of PCR 
cycles required for the final step of library prep to reduce 
PCR bias/duplicates. Early RADseq papers recommend 
as much as 1ug of starting DNA, but more recent studies 
have shown successful library prep with as little as 50-
100ng DNA per sample [19].
Error: RADseq is subject to many of the same 
sources of error that challenge all high-throughput 
sequencing studies of cancer genomics. Type II error or 
‘false negative’ mutation calls can occur if a mutation 
is present at low frequency within the tumor population 
and sequencing depth is insufficient to resolve the 
variant. RADseq may be less susceptible to this type of 
false negative than whole exome sequencing or whole 
genome sequencing because the cost-effectiveness of 
RADSeq enables greater sequencing depth per site. False 
negative mutation calls can also occur when tumors 
contain genetic heterogeneity that is not captured in a 
single biopsy. RADseq again may have advantages over 
WES and WGS with regards to this problem because the 
more cost-effective approach enables the sequencing of 
multiple spatially-independent tumor samples (multi-
region sequencing) instead of a single biopsy. Type I 
error or ‘false positive’ mutation calls also need to be 
considered in all high-throughput sequencing studies of 
tumors. False positives due to mapping errors of reads to 
the reference genome can be minimized in RADseq with 
the same bioinformatics preprocessing tools designed 
to address these problems in whole genome and whole 
exome studies, such as GATK indel realignment [54]. 
We find that mapping errors are easier to identify with 
RADseq than other sequencing methods because the 
palindromic nature of the restriction enzyme cut sites 
should result in two sets of reads independently mapping 
to the same genomic region - one from each direction of 
the cut site. False positive mutation calls can also result 
from PCR errors occurring during the library preparation. 
These errors need to be addressed differently in RADseq 
than whole genome or whole exome studies, as we discuss 
in detail below.
PCR errors and duplicates: Like most next-
generation sequencing library preparation protocols, 
RADseq methods include a PCR step to enrich for 
fragments that have successfully ligated sequencing 
adapters. This amplification can potentially lead to 
erroneous downstream mutation calls, if duplicates that 
contain PCR errors appear as mutations. The standard 
method to eliminate PCR duplicates from whole-genome 
and whole-exome sequence libraries involves removing 
reads that start and end at the exact same genomic position. 
This method is not appropriate for RADseq libraries 
because reads consistently begin at the restriction enzyme 
cut site. To eliminate PCR duplicates from RADseq data, 
several alternative methods are available. One option is to 
use paired-end sequencing (i.e. sequence the randomly-
sheared end of the DNA as well as the cut-site end, to 
remove reads with identical start and end positions). 
Alternatively, parallel PCR reactions can be performed 
for each sample and sequenced in separate lanes. Our 
preferred method is to use multiple barcodes for each 
individual sample (introduced as a mixture during library 
prep) and ensure that mutations identified at a particular 
locus are confirmed by reads containing different barcodes 
(and thus not the result of PCR error and duplication). The 
use of multiple barcodes also increases the complexity 
of the library, which leads to better cluster identification 
on the Illumina platform. A final way to eliminate PCR 
duplicates is to eliminate the PCR step of library prep 
altogether, but this requires higher starting quantities of 
genomic DNA.
Reagents: The RADseq protocol requires an initial 
financial investment in specialized barcoded adapters, 
but adapter sequences are non-proprietary and a single 
set of oligonucleotides is sufficient for a large number of 
libraries. Additionally, the same set of adapters can be used 
for compatible sets of enzymes that leave the same sticky 
end. For example, the two enzymes used in this study 
(SbfI and NsiI) leave the same ACGT overhang, so we 
were able to use a single set of adapter oligos to produce 
libraries from both restriction enzymes. The same set of 
barcoded adapter oligos can also be used for different 
species, as we demonstrate with human and zebrafish.
CONCLUSIONS
Many studies of evolution in cancer are more 
limited by the number of individuals or tissues sampled 
than by the density of markers in the genome, and for 
these studies RADseq will be an especially useful tool. 
Like other reduced-representation approaches, RADseq 
provides advantages over whole genome sequencing, such 
as greater depth of coverage per locus and the sequencing 
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of higher numbers of samples for a given budget. RADseq 
also offers an alternative to whole-exome sequencing 
because it captures more neutrally-evolving sites and 
thus produces more reliable markers to measure intrinsic 
mutation rates and to infer phylogenetic relationships than 
sites under strong positive or purifying selection. Our 
results demonstrate that RADseq can be an effective tool 
to identify single-nucleotide variants and copy number 
alterations in humans and animal models. Our detection 
of somatic changes in normal tissue of adult zebrafish also 
indicates that RADseq can be useful for studies of somatic 
mosaicism in development. The transgenic zebrafish 
that we created can also be used with RADseq to detect 
mutations in subclonal lineages.
EXPERIMENTAL PROCEDURES
Animal husbandry
All zebrafish were housed in a temperature (28.5C) 
and light-controlled (14h on, 10h off) room. Fish were 
housed at a density of 5 fish per liter, and fed 3 times 
per day using brine shrimp and pelleted zebrafish food. 
All procedures adhered to IACUC protocol #12-05-008 
through Memorial Sloan Kettering Cancer Center, as 
described previously [55].
Zebrafish tissue dissection and DNA extraction
Adult zebrafish were anesthetized in 0.2% Tricaine 
and then euthanized by incubation in ice water for 15 
minutes. Tissues were dissected according to the protocol 
and video published at http://www.jove.com/video/1717/ 
[56]. Blood was collected according to the protocol and 
video published at http://www.jove.com/video/3865/ [57]. 
DNA was extracted from dissected tumors and normal 
tissue using the DNeasy Blood & Tissue Kit (Qiagen), 
with an RNAse A treatment step. 
Library preparation
RADseq libraries were prepared from extracted 
DNA according to the method described by Etter et al [22, 
23] using the enzymes SbfI-HF and NsiI (New England 
Biolabs), with 1μg of DNA starting material. The shearing 
step was performed on a Bioruptor+ sonication device 
(Diagenode) with 10 cycles of 30 seconds on, 1 minute 
off (high setting). Zymo DNA Clean and Concentrator kits 
(Zymo Research) were used for each clean-up step. The 
final PCR amplifications were run for 12 cycles. We did 
not pool samples after the P1 ligation — all samples were 
barcoded and processed separately until final quantification 
with a Qubit fluorometer (Thermo Scientific) before being 
combined proportionately for multiplexed sequencing. 
Four different barcodes were used for each sample to 
increase library complexity and assist in eliminating PCR 
errors in downstream processing.
Human tissue dissection and library prep
Tissue sample processing. The patient and tissues 
were collected through the Johns Hopkins Gastrointestinal 
Cancer Rapid Medical Donation program [58]. Informed 
consent was obtained. Upon opening the body cavity, 
the entire primary tumor and remaining normal pancreas 
were dissected along with each metastasis. All tumor and 
normal tissues were flash-frozen in liquid nitrogen and 
stored at -80oC. The primary tumor was sliced (0.5 cm 
thick) and sectioned into 1x1 cm samples as described 
previously [11]. Macrodissection of each metastasis 
removed non-neoplastic tissue.
Genomic DNA extraction and quantification. 
A phenol and chloroform method was used to 
extract genomic DNA (gDNA) from each tumor 
sample followed by LINE assay quantification (i.e. 
counting long interspersed elements (LINE) using 
real-time PCR). The LINE forward primer used was 
5’-AAAGCCGCTCAACTACATGG-3’ and the reverse 
primer was 5’-TGCTTTGAATGCGTCCCAGAG-3’. 
The PCR protocol implemented was 50°C for 2 min, 95°C 
for 2 min, 40 cycles of 94°C for 10 s, 58°C for 15 s, and 
70°C for 30 s, 95°C for 15 s, and 60°C for 30 s. All PCR 
reactions used Platinum SYBR Green qPCR mastermix 
(Invitrogen).
Whole genome sequencing and alignment. 
Sequencing libraries were prepared using standard 
methods for each gDNA sample. Whole genome 
sequencing (WGS) utilized an Illumina Hi-Seq 2000 
platform for 60x target coverage. Sequencing reads were 
aligned to the hg19 human reference genome.
Transgenic zebrafish generation
Melanoma-prone zebrafish 
Tg(mitfa:BRAF(V600E)); p53-/- [28] were crossed with the 
ubi;Switch zebrafish line (ubi:loxP- GFP-loxP-mCherry) 
[39]. A plasmid containing mitf:CreERt2;SV40 was created 
in the pDestTol2CG2 destination vector with the Gateway 
system [59]. This plasmid (25ng/μl) was injected at 
the single cell stage using a micropipette along with 
Tol2 RNA (20ng/μl) according to previously described 
protocols [39, 60]. Embryos were treated with 20μm 
4-OHT (Sigma) at 50% epiboly. At 24 hours, the drug 
was refreshed and 0.003% of 1-phenyl-2-thiourea (PTU) 
was applied to temporarily block pigment production in 
melanocytes and aid in the visualization of fluorophores 
[61]. Larvae were imaged at 3dpf to look for color change 
in melanocytes from GFP to mCherry. Fish that showed 
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strong and specific switching were grown up and then in-
crossed to produce an F2 population that was also treated 
and imaged to confirm incorporation of the transgene in 
the germline. These fish were grown up and genotyped 
to select for individuals that carry both homozygous 
mutations required for the development of melanoma as 
well as demonstrating the strong and specific switching 
of melanocytes from GFP to mCherry after tamoxifen 
treatment. These fish were used to generate a stable line 
and for the sequencing in this study. 
Tissue digestion and FACS sorting
Adult fish were dissected as described above and the 
excised tissue was placed in an Eppendorf tube containing 
500 μL liberase diluted in DMEM media without serum 
(final: 0.15U/ml). A mini pestle was used to mechanically 
dissociate the cells. Tubes were then incubated at 37°C 
until the cells appeared to be completely dissociated in 
the solution. 500 μL of DMEM10 media (with serum) 
was added to stop the liberase activity. The cells were 
then pelleted by centrifugation at 500 RCF for 5 min in a 
refrigerated centrifuge. The supernatant was discarded and 
cells resuspended in PBS buffer. The solution was filtered 
into a FACS tube through a 40 μm mesh filter, with Dapi 
(1:100). mCherry positive cells were separated from GFP 
positive cells on an Aria III FACS machine with gating set 
by controls from pure populations of zebrafish in vitro cell 
lines. DNA was extracted from sorted cells as described 
above.
Sequencing method
All sequencing was performed on an Illumina 
HiSeq 2500 at the University of Oregon. Single-end reads 
of 100bp or 150bp were generated, and raw reads were 
exported for downstream analysis.
Informatics analysis
Filtering for quality. Each lane of data was 
processed with STACKS [62, 63], through the process_
radtags pipeline, which checks for intact barcodes and 
cut-sites and sorts reads by barcodes into separate files. 
The pipeline also filters for quality using a sliding window 
approach and reads were discarded if the score dropped 
below 90% probability of being correct. The sliding 
window was set to 15% of the length of the read. Pre-
processing. Reads passing the initial quality filter were 
pre-processed as described in GATK “best practices” 
[54, 64, 65] with the exception of the de-duplication step 
because that step is incompatible with RADseq data (see 
removing PCR duplicates above). Reads were aligned 
to the zebrafish (danRer7) or human (hg19) reference 
genomes using BWA [33]. Mutation calling. Mutation-
calling was done using MuTect [34]. Manual curation. 
The mutation lists generated by MuTect were curated 
via manual inspection of the alignment files at each 
location using the Integrative Genomics Viewer (IGV) 
[66]. Mutations in regions with problematic mapping or 
asymmetrical coverage of RADseq reads on each side of 
the cut site were omitted.
Copy-number alteration
Restriction sites were located in the zebrafish 
genome (danRer7 assembly) via in silico digestion of 
SbfI. Only reads that perfectly matched the location of 
restriction sites were retained to calculate the coverage 
of the sites. To depress the fluctuation of read depth, 
we merged 5 consecutive restriction sites as a unit, and 
walked along the chromosome via a sliding-window 
to calculate average count read number in each unit. 
The read depth ratio for each unit of the tested sample 
was calculated by dividing corresponding value in liver 
sample of melanoma-prone strain or wild-type strain 
after normalization of total reads counts. The R package 
“DNAcopy” was used to segment the chromosome via 
read depth ratio of each tested sample. To resolve the 
hyper-segmentation, the FastCall algorithm [67] was 
used to merge neighboring segments with similar copy 
numbers.
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Statement of significance
Cancer evolution plays a significant role in drug 
resistance and metastasis, but its study is limited by 
current approaches. We implement RADseq to analyze 
cancer evolution, which allows for an unbiased view of 
genome evolution in time and space. It can be applied to 
human and animal models, opening up the field to new 
investigators.
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